Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction

This study is ongoing, but not recruiting participants.
National Heart, Lung, and Blood Institute (NHLBI)
University of Florida
University of Pittsburgh
Information provided by (Responsible Party):
Noel Bairey Merz, Cedars-Sinai Medical Center Identifier:
First received: January 28, 2009
Last updated: March 23, 2017
Last verified: March 2017

This research study is designed to investigate the approaches to noninvasive detection and assessment of coronary vascular dysfunction in women by comparing the testing results from the invasive standard care diagnostic procedure Angiogram and from the additional noninvasive diagnostic procedure CMR Imaging. The investigators want to specifically study 375 female patients who have signs or symptoms suggestive of heart disease but don't have obstructive coronary artery disease. Two study sites (Cedars-Sinai Medical Center and University of Florida) are recruiting participants.

The standard of care procedures include demographics, review of recent clinical symptoms, review of medications being taken, a physical exam, pre-angiogram blood collection, chest x-ray, ECG and heart angiogram. The research procedures for this study are the cold pressor testing, blood/urine collection, health questionnaire, the post-angiogram ECG and cardiac MRI.

Patients will be asked to undergo heart angiogram testing to test for abnormalities in their heart arteries. If the heart angiogram shows that the patients do not have blockages in major heart arteries, then the patients will have coronary flow reserve measurement test (as part of the heart angiogram) to determine whether the patients have abnormally functioning of the small heart arteries. This test will be performed by infusing the three drugs: adenosine, acetylcholine and nitroglycerin. The three drugs are naturally occurring substances and have been used for routine heart angiograms.

Cardiac Magnetic Resonance (CMR) imaging may help us more easily and non-invasively detect abnormalities in the inner layer of the heart muscle resulting from the abnormal function of the heart arteries. All the 375 participants will undergo baseline CMR imaging test and a subgroup of 200 participants will undergo a second CMR imaging test at their at least 1-year followup visit.

Patients will be followed up using phone questionnaires at 6 weeks, 6 months for 5 years, and than annually for 20 years thereafter. Other procedures in this study include obtaining informed consent, review of demographics, physical examination, ECG, blood and urine tests, clinical symptoms, medications, questionnaires, etc. The core laboratories include Blood, Lipoprotein, Chemistry Core Lab, Reproductive Hormone Core Lab, Inflammatory Marker Core Lab, Oxidative Stress Core Lab, and Angiographic Core Lab. Additionally, GCRC at Cedars Sinai will process, store and ship samples as needed/required.

Condition Intervention
Cardiovascular Disease
Procedure: Cardiac MRI

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction

Further study details as provided by Cedars-Sinai Medical Center:

Primary Outcome Measures:
  • Abnormal cardiac magnetic resonance imaging (CMRI) [ Time Frame: 1 year ]
    Subjects will be contacted at 1-year followup.

Secondary Outcome Measures:
  • Resource utilization and costs [ Time Frame: up to 20 years ]
    Annual costs will include cardiovascular hospitalizations, coronary revascularizations and angiography, outpatient testing, and visits to generalists, specialists, nurse practitioners/ physician's assistants, or community clinics.

  • Persistent Chest Pain Symptoms [ Time Frame: up to 20 years ]
    Detailed information on chest pain symptoms will include the traditional angina questionnaire and the WISE female angina questionnaire

  • Quality of Life Outcomes [ Time Frame: up to 20 years ]
    Quality of life and functional capacity will be collected using the standard instruments of SAQ and DASI

Biospecimen Retention:   Samples With DNA
Blood sample will be collected for future genetic studies to better understand heart artery disease by identifing genetic factors that contribute to heart artery disorders, and for extraction and creation of cell lines.

Estimated Enrollment: 433
Actual Study Start Date: September 17, 2008
Estimated Study Completion Date: August 31, 2020
Estimated Primary Completion Date: August 31, 2020 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Cardiac MRI
    CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
Detailed Description:
See Brief Summary above.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women undergoing clinically-ordered coronary angiography for suspected ischemia will be recruited. See the inclusion and exclusion criteria for details.

Inclusion Criteria:

  1. Symptomatic angina or anginal equivalent;
  2. Aged 18 years or older;
  3. No obstructive CAD at coronary angiography (performed within the previous 24 months).
  4. Competent to give informed consent.

Exclusion Criteria:

  1. Obstructive CAD ≥ 50% luminal diameter stenosis in ≥ 1 epicardial coronary artery,
  2. Acute coronary syndrome (defined by the ACC/AHA criteria, Braunwald 2000),
  3. Primary valvular heart disease clearly indicating the need for valve repair or replacement;
  4. Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support;
  5. Prior or planned percutaneous coronary intervention or CABG,
  6. Acute MI;
  7. Prior non-cardiac illness with an estimated life expectancy < 4 years;
  8. Unable to give informed consent;
  9. Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm);
  10. Contraindications to CMRI (e.g., AICD, pacemaker, untreatable claustrophobia or known angio-edema).
  11. Contraindications to adenosine or Regadenoson (Lexiscan)
  12. Women with intermediate coronary stenoses (> 20% but < 50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgment of the operator; those determined to have flow-obstructing stenosis will be excluded from the overall study.
  13. Participation in a research study that conflicts with the current WISE study.
  14. Women with coronary stenosis ≥ 50% in any epicardial coronary artery, assessed visually at the time of angiography, will not be included in the CRT subgroup.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00832702

United States, California
Cedars-Sinai Barbra Streisand Women's Heart Center
Los Angeles, California, United States, 90048
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610-0277
Sponsors and Collaborators
Cedars-Sinai Medical Center
National Heart, Lung, and Blood Institute (NHLBI)
University of Florida
University of Pittsburgh
Principal Investigator: C. Noel Bairey Merz, MD, FACC Cedars-Sinai Medical Center
Principal Investigator: Carl J Pepine, MD, MACC University of Florida
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Noel Bairey Merz, Director, Cedars-Sinai Medical Center Identifier: NCT00832702     History of Changes
Other Study ID Numbers: IRB# 14906
5R01HL090957 ( US NIH Grant/Contract Award Number )
Study First Received: January 28, 2009
Last Updated: March 23, 2017
Individual Participant Data  
Plan to Share IPD: Yes

Keywords provided by Cedars-Sinai Medical Center:
Coronary Vascular Dysfunction

Additional relevant MeSH terms:
Cardiovascular Diseases
Pathologic Processes processed this record on April 21, 2017